Maximizing the potential of bevacizumab in cancer treatment

Oncologist

Volumn 9, Issue SUPPL. 1, 2004, Pages 36-42

  Bergsland, Emily ^a   Dickler, Maura N ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Bevacizumab; Chemotherapy; Clinical trials; Solid tumors

Indexed keywords

BETA INTERFERON; BEVACIZUMAB; CARBOPLATIN; ERLOTINIB; PACLITAXEL; PEGINTERFERON BETA2B; RITUXIMAB; THALIDOMIDE; TRASTUZUMAB; UNCLASSIFIED DRUG;

ANGIOGENESIS; BLEEDING; BREAST CANCER; CANCER RADIOTHERAPY; CANCER SURVIVAL; CANCER THERAPY; CLINICAL PRACTICE; CLINICAL TRIAL; COLORECTAL CANCER; CONFERENCE PAPER; DRUG DOSE REGIMEN; DRUG MECHANISM; EPISTAXIS; HUMAN; HYPERTENSION; MAXIMUM TOLERATED DOSE; MULTIDRUG RESISTANCE; MULTIMODALITY CANCER THERAPY; NEPHROTIC SYNDROME; PATIENT SELECTION; PRIORITY JOURNAL; PROTEINURIA; SOLID TUMOR; THROMBOEMBOLISM;

ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; HUMANS; NEOPLASMS; PATIENT SELECTION; TUMOR MARKERS, BIOLOGICAL; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 2942558419     PISSN: 10837159     EISSN: None     Source Type: Journal    
DOI: 10.1634/theoncologist.9-suppl_1-36     Document Type: Conference Paper

References (27)

1. Kabbinavar F, Hurwitz H, Fehrenbacher L et al. Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J Clin Oncol 2003;21:60-65.
2. Hurwitz H, Fehrenbacher L, Novotny W et al. Bevacizumab plus irinotecan, 5-fluorouracil, and leucovorin for the treatment of metastatic colorectal cancer: results of a randomized phase III trial. N Engl J Med 2004 (in press).
3. De Vore R, Fehrenbacher L, Herbst R et al. A randomized phase II trial comparing rHumAb VEGF (recombinant humanized monoclonal antibody to vascular endothelial growth factor) plus carboplatin/paclitaxel (CP) to CP alone in patients with stage III/IV NSCLC. Proc Am Soc Clin Oncol 2000;19:485a.
4. Yang JC, Haworth L, Sherry RM et al. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 2003;349:427-434.
5. Data on file. South San Francisco, CA: Genentech, Inc., 2002.
6. Lin YS, Nguyen C, Mendoza JL et al. Preclinical pharmacokinetics, interspecies scaling, and tissue distribution of a humanized monoclonal antibody against vascular endothelial growth factor. J Pharmacol Exp Ther 1999;288:371-378.
7. Gordon MS, Margolin K, Talpaz M et al. Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer. J Clin Oncol 2001;19:843-850.
8. Cobleigh MA, Langmuir VK, Sledge GW et al. A phase I/II dose-escalation trial of bevacizumab in previously treated metastatic breast cancer. Semin Oncol 2003;30(suppl 16):117-124.
9. Miller KD, Rugo HS, Cobleigh MA. Phase III trial of capecitabine (Xeloda©) plus bevacizumab (Avastin™) versus capecitabine alone in women with metastatic breast cancer (MBC) previously treated with an anthracycline and a taxane. Breast Cancer Res Treat 2002;76(suppl 1):S37.
10. Jain RK. Delivery of molecular medicine to solid tumors: lessons from in vivo imaging of gene expression and function. J Control Release 2001;74:7-25.
11. Kerbel R, Folkman J. Clinical translation of angiogenesis inhibitors. Nat Rev Cancer 2002;2:727-739.
12. Poon RT, Fan ST, Wong J. Clinical implications of circulating angiogenic factors in cancer patients. J Clin Oncol 2001;19:1207-1225.
13. Hanahan D, Bergers G, Bergsland E. Less is more, regularly: metronomic dosing of cytotoxic drugs can target tumor angiogenesis in mice. J Clin Invest 2000;105:1045-1047.
14. Kerbel RS. Clinical trials of antiangiogenic drugs: opportunities, problems, and assessment of initial results. J Clin Oncol 2001; 19(suppl):45S-51S.
15. Kerbel RS, Klement G, Pritchard KI et al. Continuous low-dose anti-angiogenic/metronomic chemotherapy: from the research laboratory into the oncology clinic. Ann Oncol 2002;13:12-15.
16. Gately S, Kerbel R. Antiangiogenic scheduling of lower dose cancer chemotherapy. Cancer J 2001;7:427-436.
17. Browder T, Butterfield CE, Kräling BM et al. Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. Cancer Res 2000;60:1878-1886.
18. 165 mediates glomerular endothelial repair. J Clin Invest 1999;104:913-923.
19. Alvarez Arroyo A, Castilla MA, Gonzalez Pacheco FR et al. Role of vascular endothelial growth factor on erythropoietin-related endothelial cell proliferation. J Am Soc Nephrol 1998;9:1998-2004.
20. Henry TD, Rocha-Singh K, Isner JM et al. Intracoronary administration of recombinant human vascular endothelial growth factor to patients with coronary artery disease. Am Heart J 2001;142:872-880.
21. Shen BQ, Lee DY, Zioncheck TF. Vascular endothelial growth factor governs endothelial nitric-oxide synthase expression via a KDR/Flk-1 receptor and a protein kinase C signaling pathway. J Biol Chem 1999;274:33057-33063.
22. Granger JP, Alexander BT. Abnormal pressure-natriuresis in hypertension: role of nitric oxide. Acta Physiol Scand 2000;168:161-168.
23. Langmuir VK, Cobleigh MA, Herbst RS et al. Successful long-term therapy with bevacizumab (Avastin) in solid tumors. Proc Am Soc Clin Oncol 2002;21:9a.
24. Cascinu S, Graziano F, Catalano V et al. Differences of vascular endothelial growth factor (VEGF) expression between liver and abdominal metastases from colon cancer. Implications for the treatment with VEGF inhibitors. Clin Exp Metastasis 2000;18:651-655.
25. André T, Kotelevets L, Vaillant JC et al. Vegf, Vegf-B, Vegf-C and their receptors KDR, FLT-1 and FLT-4 during the neoplastic progression of human colonic mucosa. Int J Cancer 2000;86:174-181.
26. Hillan KJ, Koeppen HKW, Tobin P et al. The role of VEGF expression in response to bevacizumab plus capecitabine in metastatic breast cancer (MBC). Proc Am Soc Clin Oncol 2003;22:191.
27. Relf M, LeJeune S, Scott PA et al. Expression of the angiogenic factors vascular endothelial cell growth factor, acidic and basic fibroblast growth factor, tumor growth factor beta-1, platelet-derived endothelial cell growth factor, placenta growth factor, and pleiotrophin in human primary breast cancer and its relation to angiogenesis. Cancer Res 1997;57:963-969.